Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002

Keizo Yamaguchi, Yoshikazu Ismi, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Akira Suwabe, Ritsuko Obata, Mitsuo Kaku, Keiji Kanemitsu, Hiroshi Yoshida, Toshio Satoh, Masami Murakami, Ayako Takahashi, Kouichi Itoh, Yasuhiro Shibuya, Harushegi Kanno, Setsuko Kubo, Shigefumi MaesakiGiichi Hashikita, Jun Igari, Toyoko Oguri, Jun Okada, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Toshinobu Horii, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Tosiiiaki Komori, Satoshi Ichiyama, Shigetaka Maeda, Kiyoharu Yamanaka, Yoko Murata, Masanori Aihara, Shohiro Kinoshita, Tomohiko Taminato, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuuchika Kusano, Eiichirou Mihara, Masayum Kambe, Hideyuki Itaha, Junko Ono, Hisae Yoshimura, Yoichi Hirakata, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)

Abstract

The antibacterial activity of meropenem (MEPM) and odler paremeral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC 90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.

Original languageEnglish
Pages (from-to)70-104
Number of pages35
JournalJapanese Journal of Antibiotics
Volume57
Issue number1
Publication statusPublished - Feb 2004

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002'. Together they form a unique fingerprint.

Cite this